336 related articles for article (PubMed ID: 28651379)
1. KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas.
Tang H; Zhu H; Wang X; Hua L; Li J; Xie Q; Chen X; Zhang T; Gong Y
J Mol Cell Biol; 2017 Aug; 9(4):315-324. PubMed ID: 28651379
[TBL] [Abstract][Full Text] [Related]
2. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.
Kliese N; Gobrecht P; Pachow D; Andrae N; Wilisch-Neumann A; Kirches E; Riek-Burchardt M; Angenstein F; Reifenberger G; Riemenschneider MJ; Meese E; Panayotova-Dimitrova D; Gutmann DH; Mawrin C
Oncogene; 2013 Sep; 32(39):4712-20. PubMed ID: 23108408
[TBL] [Abstract][Full Text] [Related]
3. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
4. KLF4
von Spreckelsen N; Waldt N; Poetschke R; Kesseler C; Dohmen H; Jiao HK; Nemeth A; Schob S; Scherlach C; Sandalcioglu IE; Deckert M; Angenstein F; Krischek B; Stavrinou P; Timmer M; Remke M; Kirches E; Goldbrunner R; Chiocca EA; Huettelmaier S; Acker T; Mawrin C
Acta Neuropathol Commun; 2020 Apr; 8(1):41. PubMed ID: 32245394
[TBL] [Abstract][Full Text] [Related]
5. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
6. NANOG overexpression and its correlation with stem cell and differentiation markers in meningiomas of different WHO grades.
Freitag D; McLean AL; Simon M; Koch A; Grube S; Walter J; Kalff R; Ewald C
Mol Carcinog; 2017 Aug; 56(8):1953-1964. PubMed ID: 28345785
[TBL] [Abstract][Full Text] [Related]
7. Secretory meningioma with KLF4 K409Q mutation in collision with glioma.
Ruiz J; Capilla E; Díaz JF; Ruiz JA; Andrade J; Hernández T; Mollejo M; Meléndez B
Clin Neuropathol; 2015; 34(6):322-9. PubMed ID: 26227255
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.
Simon M; Park TW; Leuenroth S; Hans VH; Löning T; Schramm J
J Neurosurg; 2000 May; 92(5):832-40. PubMed ID: 10794298
[TBL] [Abstract][Full Text] [Related]
9. Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization.
Ishino S; Hashimoto N; Fushiki S; Date K; Mori T; Fujimoto M; Nakagawa Y; Ueda S; Abe T; Inazawa J
Cancer; 1998 Jul; 83(2):360-6. PubMed ID: 9669820
[TBL] [Abstract][Full Text] [Related]
10. The expression of disabled-2 is common reduced in meningiomas.
Zhang Z; Chen Y; Xie X; Tang J
Neurol India; 2014; 62(1):57-61. PubMed ID: 24608456
[TBL] [Abstract][Full Text] [Related]
11. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
[TBL] [Abstract][Full Text] [Related]
12. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
[TBL] [Abstract][Full Text] [Related]
13. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
Yang SY; Park CK; Park SH; Kim DG; Chung YS; Jung HW
J Neurol Neurosurg Psychiatry; 2008 May; 79(5):574-80. PubMed ID: 17766430
[TBL] [Abstract][Full Text] [Related]
14. Microarray Expression Data Identify DCC as a Candidate Gene for Early Meningioma Progression.
Schulten HJ; Hussein D; Al-Adwani F; Karim S; Al-Maghrabi J; Al-Sharif M; Jamal A; Al-Ghamdi F; Baeesa SS; Bangash M; Chaudhary A; Al-Qahtani M
PLoS One; 2016; 11(4):e0153681. PubMed ID: 27096627
[TBL] [Abstract][Full Text] [Related]
15. Malignant progression to anaplastic meningioma: Neuropathology, molecular pathology, and experimental models.
Cimino PJ
Exp Mol Pathol; 2015 Oct; 99(2):354-9. PubMed ID: 26302177
[TBL] [Abstract][Full Text] [Related]
16. Masked hypodiploidy in anaplastic meningiomas by duplication of the original clone found in atypical meningiomas: illustration of the evolution of genetic alterations.
Ely EE; Guzman MA; Calvey LS; Batanian JR
Neuropathology; 2014 Aug; 34(4):353-9. PubMed ID: 24612240
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?
Sayagués JM; Tabernero MD; Maíllo A; Espinosa A; Rasillo A; Díaz P; Ciudad J; López A; Merino M; Gonçalves JM; Santos-Briz A; Morales F; Orfao A
J Mol Diagn; 2004 Nov; 6(4):316-25. PubMed ID: 15507670
[TBL] [Abstract][Full Text] [Related]
18. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
19. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
Wrobel G; Roerig P; Kokocinski F; Neben K; Hahn M; Reifenberger G; Lichter P
Int J Cancer; 2005 Mar; 114(2):249-56. PubMed ID: 15540215
[TBL] [Abstract][Full Text] [Related]
20. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
